

Primary Myelofibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/PAE67D13B9D5EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: PAE67D13B9D5EN

Abstracts

The 7 major primary myelofibrosis markets are expected to exhibit a CAGR of 3.07% during 2024-2034.

The primary myelofibrosis market has been comprehensively analyzed in IMARC's new report titled "Primary Myelofibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary myelofibrosis refers to a rare type of severe blood cancer that affects the bone marrow. In this condition, the bone marrow becomes progressively scarred or fibrotic, leading to the disruption of normal blood cell production. The common indications of the ailment include fatigue, weakness, shortness of breath, easy bruising and bleeding, an enlarged spleen or liver, bone pain or tenderness, unexplained weight loss, excessive sweating during sleep, frequent infections, etc. The diagnosis of primary myelofibrosis typically involves a combination of medical history assessment, clinical feature review, and physical examinations. Several blood tests, such as a peripheral blood smear and complete blood count, are also conducted to evaluate the blood cell counts and identify any abnormalities. The healthcare provider will further perform imaging techniques, like ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), etc., to assess the size and condition of the spleen and liver. Additionally, a bone marrow biopsy is particularly required to determine the extent of fibrosis and to rule out other possible causes of underlying symptoms in patients.

The increasing cases of gene mutations, which affect the signaling networks involved in the regulation of blood cell production and cause abnormal cell growth, are primarily driving the primary myelofibrosis market. In addition to this, the escalating incidence of chronic inflammation and immune dysregulation that may contribute to the fibrosis and

disruption of healthy tissues is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, like Janus kinase (JAK) inhibitors, on account of their numerous advantages, such as reducing symptoms, controlling spleen enlargement, and improving quality of life in patients, is further bolstering the market growth. Apart from this, the rising application of stem cell transplantation, since it aims to eradicate the abnormal clone of stem cells responsible for the formation of fibrous tissues in the bone marrow, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immunomodulatory drugs, including thalidomide and lenalidomide, which help to restore immune balance by modulating the release of certain cytokines, is expected to drive the primary myelofibrosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the primary myelofibrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary myelofibrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary myelofibrosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary myelofibrosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary myelofibrosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary myelofibrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the primary myelofibrosis market performed so far and how will it perform in

the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the primary myelofibrosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the primary myelofibrosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of primary myelofibrosis across the seven major markets?

What is the number of prevalent cases (2018-2034) of primary myelofibrosis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of primary myelofibrosis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with primary myelofibrosis across the seven major markets?

What is the size of the primary myelofibrosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of primary myelofibrosis?

What will be the growth rate of patients across the seven major markets?

Primary Myelofibrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for primary myelofibrosis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary myelofibrosis market?

What are the key regulatory events related to the primary myelofibrosis market?

What is the structure of clinical trial landscape by status related to the primary myelofibrosis market?

What is the structure of clinical trial landscape by phase related to the primary myelofibrosis market?

What is the structure of clinical trial landscape by route of administration related to the primary myelofibrosis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PRIMARY MYELOFIBROSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PRIMARY MYELOFIBROSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PRIMARY MYELOFIBROSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.2.3 Epidemiology by Age (?2018-2034?)

7.2.4 Epidemiology by Gender (?2018-2034?)

7.2.5 Diagnosed Cases (?2018-2034?)

7.2.6 Patient Pool/Treated Cases (?2018-2034?)

7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.3.3 Epidemiology by Age (?2018-2034?)

7.3.4 Epidemiology by Gender (?2018-2034?)

7.3.5 Diagnosed Cases (?2018-2034?)

7.3.6 Patient Pool/Treated Cases (?2018-2034?)

7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.4.3 Epidemiology by Age (?2018-2034?)

7.4.4 Epidemiology by Gender (?2018-2034?)

7.4.5 Diagnosed Cases (?2018-2034?)

7.4.6 Patient Pool/Treated Cases (?2018-2034?)

7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.5.3 Epidemiology by Age (?2018-2034?)

7.5.4 Epidemiology by Gender (?2018-2034?)

7.5.5 Diagnosed Cases (?2018-2034?)

7.5.6 Patient Pool/Treated Cases (?2018-2034?)

7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.6.3 Epidemiology by Age (?2018-2034?)

7.6.4 Epidemiology by Gender (?2018-2034?)

7.6.5 Diagnosed Cases (?2018-2034?)

7.6.6 Patient Pool/Treated Cases (?2018-2034?)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 PRIMARY MYELOFIBROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PRIMARY MYELOFIBROSIS - UNMET NEEDS

10 PRIMARY MYELOFIBROSIS - KEY ENDPOINTS OF TREATMENT

11 PRIMARY MYELOFIBROSIS - MARKETED PRODUCTS

- 11.1 List of Primary Myelofibrosis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Inrebic (Fedratinib) - Celgene
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Vonjo (Pacritinib) - CTI BioPharma
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Jakafi (Ruxolitinib) - Incyte Corporation/Novartis
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 PRIMARY MYELOFIBROSIS - PIPELINE DRUGS

12.1 List of Primary Myelofibrosis Pipeline Drugs Across the Top 7 Markets

- 12.1.1 PXS-5505 - Pharmaxis
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
- 12.1.2 NS018 - Nippon Shinyaku
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 KRT232 - Kartos Therapeutics
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Selinexor - Karyopharm Therapeutics
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

12.1.5 TP 3654 - Sumitomo Pharma Oncology

12.1.5.1 Drug Overview

12.1.5.2 Mechanism of Action

12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PRIMARY MYELOFIBROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PRIMARY MYELOFIBROSIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 PRIMARY MYELOFIBROSIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Primary Myelofibrosis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Primary Myelofibrosis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Primary Myelofibrosis - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Primary Myelofibrosis - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Primary Myelofibrosis - Access and Reimbursement Overview

15.4 Market Scenario - Germany

- 15.4.1 Primary Myelofibrosis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
- 15.4.2 Primary Myelofibrosis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
- 15.4.3 Primary Myelofibrosis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Primary Myelofibrosis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Primary Myelofibrosis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Primary Myelofibrosis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Primary Myelofibrosis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Primary Myelofibrosis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Primary Myelofibrosis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Primary Myelofibrosis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Primary Myelofibrosis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Primary Myelofibrosis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Primary Myelofibrosis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Primary Myelofibrosis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Primary Myelofibrosis - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Primary Myelofibrosis - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Primary Myelofibrosis - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Primary Myelofibrosis - Access and Reimbursement Overview

16 PRIMARY MYELOFIBROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PRIMARY MYELOFIBROSIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 PRIMARY MYELOFIBROSIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Primary Myelofibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/PAE67D13B9D5EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PAE67D13B9D5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

